拉罗特雷克提尼布在患有NTRK融合瘤的患者中:来自NCI-MATCH ECOG-ACRIN试验 (EAY131) 副协议EAY131-Z1EE1的结果
Neal Akhave1, Zihe Song2, David S Hong1
1The University of Texas MD Anderson Cancer Center, Houston, TX.
JCO precision oncology
|February 20, 2026
概括
拉罗特雷克提尼布在治疗神经营性热氨酸受体激酶 (NTRK) 融合阳性癌症方面表现出显著的疗效,显示出高客观反应率和有利的安全性. 这支持其在精密医学中用于NTRK驱动的瘤的应用.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
- 精准医学是一门精准的医学.
背景情况:
- 神经断性热胺受体激酶 (NTRK) 基因融合是各种人类癌症的致癌驱动因素.
- 识别和准这些融合对于有效的癌症治疗至关重要.
- 拉罗特雷克提尼布是所有三种TRK蛋白 (TRKA,TRKB,TRKC) 的选择性抑制剂.
研究的目的:
- 为了研究larotrectinib在患有NTRK融合阳性癌症的患者中的疗效和安全性.
- 为了评估larotrectinib在NCI-MATCH (治疗选择分子分析) 试验中的表现,Z1E子协议.
主要方法:
- 在NCI-MATCH分协议Z1E中,纳入了具有NTRK融合的固体瘤或淋巴瘤的患者.
- 患者每天两次服用larotrectinib 100 mg,直到疾病进展或毒性.
- 主要终点是客观应答率 (ORR);次要终点包括无进展生存率 (PFS) 和整体生存率 (OS).
主要成果:
- 在六种组织学中,12名NTRK融合阳性瘤患者接受了larotrectinib.
- 客观反应率 (ORR) 为75%,中位数PFS为14.4个月,中位数OS为23.9个月.
- 治疗耐受性良好,主要有1级不良事件.
结论:
- 拉罗特雷克提尼布在NTRK融合阳性瘤中提供了显著的临床益处和明显的ORR.
- 该药物表现出良好的安全性,支持其组织无关的批准.
- 包括NTRK1,NTRK2和NTRK3在内的综合分子测试对于识别可以从larotrectinib中受益的患者至关重要.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
8.0K
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.4K
相关概念视频
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
01:20The Retinoblastoma Gene
4.8K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.8K